Proposed Changes to New Zealand’s Medicines Legislation in the Medicines Amendment Bill 2011
Moore, Jennifer
This item is not available in full-text via OUR Archive.
If you are the author of this item, please contact us if you wish to discuss making the full text publicly available.
Cite this item:
Jennifer Moore "Proposed Changes to New Zealand’s Medicines Legislation in the Medicines Amendment Bill 2011" (2013) 10(1) JBI 59.
Permanent link to OUR Archive version:
http://hdl.handle.net/10523/6149
Abstract:
This article evaluates New Zealand’s Medicines Amendment Bill 2011. This Bill is currently before Parliament and will amend the Medicines Act 1981. On June 20, 2011, the Australian and New Zealand governments announced their decision to proceed with a joint scheme for the regulation of therapeutic products such as medicines, medical devices, and new medical interventions. Eventually, the joint arrangements will be administered by a single regulatory agency: the Australia New Zealand Therapeutic Products Agency. The medicines regulations in Australia and New Zealand will be updated as part of this process. The Medicines Amendment Bill addresses some of the well-recognised deficiencies in the Medicines Act 1981. However, a comprehensive overhaul of the Act is not being undertaken. I argue that repealing and replacing the Medicines Act 1981 would be preferable and advisable, given the number of legal difficulties with the Act and, in particular, where it does not align with equivalent current international law.
Date:
2012
Publisher:
Springer
Pages:
59-66
ISSN:
1872-4353 (Online)
Rights Statement:
If you can say yes to all of these statements, you are ready for open access publication under a Springer Compact agreement:
My open access article has been accepted by an Open Choice eligible journal*
I am the corresponding author
I am affiliated with an eligible institution/university*
The type of my article is covered by my institution’s/university’s agreement*
Tip: To increase the chances of being recognized by the institutions as eligible, corresponding authors are advised to use their email address from the respective institution instead of their private email address.
If authors choose open access in the Springer Open Choice program, the copyright remains with them, the authors of the article.
As of January 2012, the majority of Springer’s Open Choice eligible journals publish open access articles under the liberal Creative Commons Attribution 4.0 International (CC BY) license. The CC BY license permits unrestricted use, distribution and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
A limited number of journals continue to use the Creative Commons Attribution Non-Commercial 4.0 International (CC BY-NC) license, including those published under our Adis imprint.
Keywords:
medicines legislation; pharmaceuticals; medicines; regulation of medicines; medical devices; therapeutic products
Research Type:
Journal Article
Languages:
English
Collections
- Journal Article [661]
- Law Collection [383]